On a global romp, Boehringer BD team picks up its third R&D alliance for July — this time focused on IPF with $50M upfront
Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.
They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,300+ biopharma pros reading Endpoints daily — and it's free.